Log in

Support for diabetics: "strategic alliance" between Medtronic and Sanofi


Paris, June 14 2014 (AFP) - Medtronic and Sanofi pharmaceutical companies announced on Saturday an "agreement in principle" to establish a "global alliance" to improve clinical outcomes and daily life of people with diabetes.

This alliance will focus initially on "the development of medical drugs, devices associations" and "the provision of care management to improve adherence, simplify insulin and help people with diabetes better take charge of their disease, "according to a joint statement.

It will act as "design associations medical devices and drugs-including new solutions that are affordable, practical and easy to use to improve adherence and to enable patients to achieve better clinical outcomes."

Both groups reported that their "efforts will focus on improving the management of type II diabetes in 2, especially among people who can not control blood sugar levels despite several daily insulin injections."

"We know that insulin and other diabetes represent only one aspect of treatment. Support Diabetes knows no respite and non-adherence is one of the main barriers to optimal care of this disease, "said Pascale Witz, executive vice president in charge of strategic development at Sanofi.

"It is for this reason that Sanofi is committed to developing integrated care solutions that seek to improve the lives of people with diabetes and to improve clinical outcomes to help alleviate the financial burden on health systems. Through this important collaboration, Sanofi will exploit advances in technology in order to develop comprehensive healthcare solutions that address the needs of individual patients, "she says. "

The prevalence of diabetes in the world is unfortunately increasing. This disease places a heavy financial burden on health systems and has a particularly strong negative impact on the lives of millions of people, "added Omar Ishrak, president of Medtronic.

The U.S. group said commit to "co-develop a range of technologies and services for patients to improve their clinical results at affordable prices."

The alliance will allow both groups "to share their experience, respectively insulins and drug development, and insulin pumps and continuous monitoring devices for blood glucose."

MSNA: Good conservation and use of health products in case of heat wave

Under the national heat wave plan, we remind you that information concerning the proper use and conservation of health products are available on the website of MSNA in the theme folder"Extreme weather and health products"

http://ansm.sante.fr/Dossiers/Climatic conditions-extreme-and product-of-health /Heatwave and products-of-health 

Heatwave and drugs

Documents to the attention of health professionals
-Drugs that may alter the adaptation of the body to heat - Focus

-Conservation of drugs in case of heat wave - Development
-Heatwave and extreme heat - File of Ministry of Health
-Clarification Regarding the good use of drugs in the event of a heat wave - Key messages
-Clarification on the conservation of drugs in the event of a heat wave

Documents to the attention of patients and health professionals
-Information on drug treatments in case of heat wave - Questions / Answers

Heatwave and blood glucose meters

Document to the attention of health professionals
-Focus on the conservation and use of glucose meters and their associated reagents in case of heat wave

Document to the attention of patients and health professionals
-You and monitoring your blood sugar with a glucose meter in case of heat wave

Documents relating to sun protection

Advice to users
-Good use of sunscreen products - Key Messages
-Good use of sunscreen products - Recommendations
Guide for choosing a sunscreen product

Sanofi: encouraging new tests for treatment of rheumatoid arthritis

Paris, June 12 2014 (AFP) - French pharmaceutical group Sanofi and its U.S. partner Regeneron announced Thursday it had recorded new encouraging results in a phase III clinical trial for treatment of rheumatoid arthritis by antibodies sarilumab . These positive results should be presented in Paris the day before the Annual Congress of the European League for the Fight against Rheumatism (EULAR) indicate Sanofi and Regeneron in a joint statement. Rheumatoid arthritis, which is the most common chronic inflammatory rheumatism, can become extremely debilitating if it is not treated. The clinical trial, which involved 1.197 patients with active rheumatoid arthritis moderate to severe and not responding to standard therapy with methotrexate, 52 lasted weeks, the statement said. "The sarilumab reached the three co-primary endpoints and demonstrated improvement in signs and symptoms of the disease 24 weeks, physical function 16 weeks and inhibition of progression of joint damage in 52 weeks "says the text. Patients who participated in the first phase III trial, the results of which were communicated in November, had also "presented statistically and clinically significant improvements compared to placebo group." "Despite significant progress, many patients with rheumatoid arthritis continue to have disabling symptoms and signs, which emphasizes the need for additional treatment options," said the statement Dr. Mark Genovese, professor at the American University Stanford and principal investigator of the study. Both companies now expect the results of other trials that fall within the framework of a comprehensive clinical program for the registration of this medicine. Phase III is the final step before submitting a request for placing on the market.

Ibuprofen dose: EMA will assess cardiovascular risk

Paris, June 13 2014 (AFP) - The European Medicines Agency (EMA) said Friday it has initiated a reassessment of the cardiovascular risk associated with taking large doses and repeated ibuprofen, one of the drugs most commonly used against pain and inflammation.
"Cardiovascular risk will be evaluated for a large dose of ibuprofen (2.400 mg per day) taken regularly for long periods" indicates the EMA in a statement.
The agency says, however, that "nothing to suggest" that there is such a risk with ibuprofen used by the vast majority of patients at much lower doses. Typical doses are in the order of 200 400 mg, three to four times per day. Ibuprofen is a drug marketed since 60 years under various trade names such as Advil or Nurofen.
Some forms (including 200 mg) are freely available in several European countries including France.
According to the EMA, ibuprofen "has a known safety profile" which is the subject of an assessment, including regarding its cardiovascular risk "for many years, both at European level and national ".
An analysis of existing data, cited by the EMA, the risk of high-dose ibuprofen (2.400 mg) was similar to that of the painkiller diclofenac (Voltaren and generic), whose use has been the Last year limited in patients with heart failure or a history of heart attack or stroke (CVA).
These drugs are part of the family of nonsteroidal anti-inflammatory drugs (NSAIDs), associated with a small increased risk of arterial thromboembolism may in some cases lead to cardiac infarction or stroke (CVA), especially in case of use and high dose for a long-term treatment.
The EMA said that his committee for risk assessment in pharmacovigilance (Prac) will also evaluate "the interaction between ibuprofen and low-dose aspirin used to reduce the risk of heart attack or stroke and decide whether the advice currently given to health professionals are sufficient. "
Pending completion of the review, patients are advised to continue taking their medications according to their requirements.
This does not apply gels and creams ibuprofen, but only treatments taken orally.

GM mosquitoes, a new approach that "male" against malaria

Paris, 10 June 2014 (AFP) - Rather than a new insecticide or a miracle vaccine, researchers have chosen a "male" approach to malaria control: altering mosquito chromosomes to eradicate females, Spread the epidemic. To achieve this, biologists have injected into the genome of the mosquito Anopheles gambiae - one of the main vectors of malaria in the world - a gluttonous enzyme. Named I-Ppol, this enzyme cuts DNA from the X chromosome (which produces females) during sperm production, so most of them are no longer functional, but it does not attack the Y chromosome (which produces males). After six years of hard work, the first laboratory tests resulted in the creation of a new, fully fertile, but producing 95% mosquito strain of male larvae, the Imperial College in London Research. The researchers introduced 50 male anopheline cages OGM and 50 wild-type females, and in four out of five cages the mosquito population was completely wiped out in only six generations, due to a lack of females to perpetuate the lineage. "We believe that our innovative approach is a major step forward: for the first time we have successfully prevented the outbreak of females in the laboratory, which could help eliminate malaria," said Andrea Crisanti of the Department of Science Of the life of Imperial College. Since 2000, measures to control mosquito populations and to strengthen prevention have reduced the malaria mortality of 42%, but this disease still kills more than 600.000 every year, especially in sub-Saharan Africa . And these measures are increasingly faced with the emergence of insecticide-resistant mosquitoes or the development of treatment-resistant strains of malaria. "What is very promising is that once the genetically modified mosquitoes are introduced, the males will essentially produce males, and their sons will do the same. It is the mosquitoes who will do the work for us, Nikolai Windbichler, who directed this work at Imperial College, published Tuesday in the journal Nature Communications. Similar experiments are already underway in Brazil and Malaysia to control dengue, a viral infection spread by another mosquito species, Aedes aegypti. In this case, mosquitoes have been genetically modified to produce larvae that will not reach adulthood and therefore will never be able to stick humans.


a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )

  group    administrators A3P
& Project Managers

letter   newsletter A3P